ITGB8 — patent landscape

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5245551	0.59	12/20
SCHEMBL5245561	0.59	12/20
SCHEMBL5246827	0.59	12/20
SCHEMBL5246207	0.67	11/20
SCHEMBL5248510	0.64	11/20
SCHEMBL5247425	0.64	11/20
SCHEMBL5248140	0.64	11/20
SCHEMBL5245865	0.64	11/20
SCHEMBL5246415	0.64	11/20
SCHEMBL5246943	0.64	11/20
SCHEMBL5248041	0.64	11/20
SCHEMBL5248050	0.64	11/20
SCHEMBL5245978	0.61	11/20
SCHEMBL5246840	0.56	11/20
SCHEMBL5246844	0.56	11/20
SCHEMBL5247605	0.49	11/20
SCHEMBL2838721	0.47	11/20
SCHEMBL2836750	0.46	11/20
SCHEMBL5246353	0.71	10/20
SCHEMBL1243228	0.61	10/20

Clinical trials — most relevant to ITGB8 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
The Outcomes of ICSI Cycles With and Without Letrozole	PHASE4	UNKNOWN
First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor.	PHASE1/PHASE2	RECRUITING
Monoclonal Antibody Therapy in Treating Patients With Advanced Colorectal Cancer	PHASE1/PHASE2	COMPLETED
Interferon Gamma to Treat Leukocyte Adhesion Deficiency Type I	PHASE2	COMPLETED
A Gene Therapy Trial to Evaluate the Safety and Efficacy of RP-L201 in Subjects With Leukocyte Adhesion Deficiency-I	PHASE1	WITHDRAWN
A Study to Evaluate Adverse Events and How the Drug Moves Through the Body From Subcutaneous (SC) and Intravenous (IV) Doses of ABBV-382 in Healthy Adult Chinese Volunteers	PHASE1	COMPLETED
Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors	PHASE1	COMPLETED
Vedolizumab (Anti-alpha4beta7) in Subjects With HIV Infection Undergoing Analytical Treatment Interruption	PHASE1	COMPLETED
68Ga-NOTA-PRGD2 PET/CT in Patients With Lung Injury and Pulmonary Fibrosis	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Patients With Rheumatoid Arthritis	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Diagnosis and Evaluation of Glioma	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Stroke	EARLY_PHASE1	UNKNOWN
68Ga-BNOTA-PRGD2 PET/CT in Evaluation of Myocardial Infarction	EARLY_PHASE1	UNKNOWN
99mTc-3PRGD2 SPECT/CT in Rheumatoid Arthritis Patients	EARLY_PHASE1	COMPLETED
An Open-label, Single-arm, Single-center Study to Evaluate the Diagnostic Efficacy of a Novel PET Probe, 68Ga-SFB6-ZN01, in Patients With Malignant Tumors	EARLY_PHASE1	NOT_YET_RECRUITING
68Ga-BNOTA-PRGD2 PET/CT in Healthy Volunteers and Lung Cancer Patients	EARLY_PHASE1	UNKNOWN
Anti-αIIbβ3 Immunization in Glanzmann Thrombasthenia: Prevalence and Associated Risk Factors: Thrombasthenia Anti-αIIbβ3 Antibodies Study (TAAS)	nan	COMPLETED
The Role of CD4+ T Cell Subsets in the Mechanism of Action of Vedolizumab in Ulcerative Colitis	nan	UNKNOWN
Angiogenesis and Fibrosis in Myocardial Infarction	nan	COMPLETED
The Role of Platelet Surface α2β1 Integrin Expression as a Risk Factor in Thrombotic and/or Bleeding Complications	nan	COMPLETED
Angiogenesis and Fibrosis in Aortic Stenosis	nan	COMPLETED
IMaging Pilot Study of the αvβ6 Integrin Radiotracer [18F]-A20FMDV2 in PAtients With Solid Cancer Types	nan	COMPLETED
Ischemic Preconditioning of Liver in Cadaver Donors	nan	COMPLETED
Effect of Mepolizumab on Severe Eosinophilic Asthma	nan	UNKNOWN
ITGA2b and SELP Expression in Cancer Pancreas and Biliary Tract Cancer	nan	UNKNOWN
Early Regenerative Intervention for Post-Traumatic Osteoarthritis	nan	UNKNOWN
Clinical Study of 18F-FAPI-RGD in Ovarian Cancer	nan	COMPLETED
Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis	nan	COMPLETED
Potential Role of microRNA 410 and BIRC7 Pathways in Recurrent Spontaneous Miscarriage	nan	COMPLETED
Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a ITGB8 binder may also engage these)

Protein	Name	Similarity
P26013	—	0.998	P26013 →
Q0VBD0	—	0.996	Q0VBD0 →
ITGB5	Integrin beta-5	0.975	landscape →
O70309	—	0.974	O70309 →
O95980	—	0.970	O95980 →
ITGB3	Integrin beta-3	0.967	landscape →
P80747	—	0.965	P80747 →
Q8BFR2	—	0.965	Q8BFR2 →
A0A1D5PUP4	—	0.963	A0A1D5PUP4 →
Q3V3R4	—	0.962	Q3V3R4 →
Q9Z0J1	—	0.962	Q9Z0J1 →
Q8N475	—	0.962	Q8N475 →
Q9HCM2	—	0.961	Q9HCM2 →
ITGA1	Integrin alpha-1	0.961	landscape →
P18614	—	0.960	P18614 →
Q07441	—	0.959	Q07441 →
O54890	—	0.958	O54890 →
Q9P0K1	—	0.957	Q9P0K1 →
P27090	—	0.956	P27090 →
Q99J86	—	0.956	Q99J86 →
A8WCC4	—	0.955	A8WCC4 →
P61811	—	0.955	P61811 →
Q6DFV5	—	0.955	Q6DFV5 →
P70207	—	0.955	P70207 →
P21674	—	0.954	P21674 →
ENPP2	Autotaxin	0.954	landscape →
O75051	—	0.954	O75051 →
HELZ	Probable helicase with zinc finger domain	0.954	landscape →
A5YT95	—	0.954	A5YT95 →
TGFB2	Transforming growth factor beta-2 proprotein	0.954	landscape →